Digital Pathology Market Global Industry Outlook, Opportunity Analysis and Forecast 2020-2025

Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=195916

The Global Digital Pathology Market is projected to reach USD 1,054 Million by 2025 from USD 553 Million in 2020, at a CAGR of 13.8% during the forecast period. This report spread across 210 Pages, Profiling 16 Companies and Supported with 192 Tables and 42 figures are now available in this research.

Top Key Players Profiled in the Digital Pathology Market:

  • Leica Biosystems (US)
  • Koninklijke Philips N.V. (Netherlands)
  • Hamamatsu Photonics K.K. (Japan)
  • Roche (Switzerland)
  • 3DHISTECH (Hungary)
  • Apollo Enterprise Imaging (US)
  • XIFIN (US)
  • Huron Digital Pathology (Canada)
  • Visiopharm A/S (Denmark)
  • Corista (US)
  • Indica Labs (US)
  • Objective Pathology Services (Canada)
  • Sectra AB (Sweden)
  • OptraSCAN (India)
  • Glencoe Software (US)
  • KONFOONG BIOTECH INTERNATIONAL CO.LTD (China)
  • Inspirata Inc. (US)
  • Mikroscan Technologies (US)
  • Proscia Inc. (US)
  • Kanteron Systems (Spain)

 

The adoption of AI in healthcare has been rising in recent years due to its ability to optimize clinical processes, thereby solving a variety of problems in the healthcare industry. AI helps patients receive correct diagnosis in a timely manner, maximize hospital efficiency, and reduce the waiting time for patients, thereby enhancing overall healthcare.

 

Access full report with all information @ https://www.reportsnreports.com/purchase.aspx?name=195916

 

On the basis of product, the digital pathology market is segmented into scanners, software, communication systems, and storage systems. The scanners segment accounted for the largest share of the digital pathology market in 2019. The large share of this segment is mainly due to the increasing adoption of digital pathology solutions across the globe, and the high cost of scanners.

 

Breakdown of primary participants’ profile:

  • By Company Type (Supply-side): Tier 1: 29%, Tier 2: 37%, and Tier 3: 34%
  • By Category (Demand-side): Pharmaceutical & Biotechnology Companies: 55%, Hospitals and Reference Laboratories: 35%, and Academic & Research Institutes: 10%
  • By Designation: C-level: 35%, Director-level: 25%, and Managers: 40%
  • By Region: North America: 35%, Europe: 32%, Asia: 22%, and the RoW: 11%

 

Share This Post